Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 11:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 517 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: testosterone Clear all
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

NCT00203996
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
Device · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Phase 3 Interventional

Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism

NCT01619683
View directory record Official record
Conditions
Effect of Treatment on Bone Mineral Density
Interventions
enclomiphene citrate, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
17
States / cities
Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 18, 2026, 11:57 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

NCT05241860
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
Interventions
Pharmacotherapy Discontinuation, Follow-Up, Questionnaire Administration, Quality-of-Life Assessment
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
326
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 234 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone

NCT00161421
View directory record Official record
Conditions
Contraception, Hypogonadism
Interventions
Oral Testosterone, Leuprolide (Lupron), Dutasteride
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2008 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

NCT02090114
View directory record Official record
Conditions
Prostate Cancer
Interventions
Testosterone cypionate, Testosterone Enanthate, Abiraterone acetate, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance

NCT02286921
View directory record Official record
Conditions
Castration Resistant Metastatic Prostate Cancer
Interventions
Testosterone cypionate, Enzalutamide, Testosterone Enanthate
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception

NCT03452111
View directory record Official record
Conditions
Healthy, Men, Male Contraception
Interventions
Nestorone + Testosterone Combination Gel
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
9
States / cities
Sacramento, California • Torrance, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 18, 2026, 11:57 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Comparison of Salivary and Serum Free Testosterone in Normal and Hypogonadal Men

NCT01909505
View directory record Official record
Conditions
Known Androgen Deficiency
Interventions
Not listed
Lead sponsor
Saliva Biomarkers, Inc.
Industry
Eligibility
20 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Not applicable Interventional Results available

Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY/Klinefelter Syndrome

NCT01585831
View directory record Official record
Conditions
Klinefelter Syndrome, XXY Syndrome
Interventions
Testosterone gel 1%, Placebo gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 18 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 18, 2026, 11:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Endometriosis and Migraine

NCT06785129
View directory record Official record
Conditions
Migraine, Endometriosis
Interventions
Thermal stimuli, Pressure stimuli, Pain ratings, Conditioned pain modulation (CPM) response, Hormonal assessment
Device · Behavioral · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

NCT02730169
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
BGS649, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Phase 2 Interventional

The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers

NCT00900900
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
dehydroepiandrosterone (DHEA), pregnenolone, Placebo
Dietary Supplement · Drug
Lead sponsor
Jed E. Rose
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2012 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cardiovascular Outcomes of Low Testosterone

NCT02758431
View directory record Official record
Conditions
Hypogonadism
Interventions
Acyline, Placebo Gel, Placebo Tablet, Testosterone Gel, Arimidex
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Phase 3 Interventional Results available

Testosterone Administration and ACL Reconstruction in Men

NCT01595581
View directory record Official record
Conditions
Muscle Atrophy, ACL Reconstruction, Trauma, Osteoarthritis
Interventions
Testosterone, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Safety, and Sperm and Gonadotropin Suppression of a Contraceptive Gel in Normal Men

NCT00891228
View directory record Official record
Conditions
Contraception
Interventions
Testosterone, Nestorone®
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Androgen Administration on Inflammation in Normal Women

NCT01753037
View directory record Official record
Conditions
Hyperandrogenism
Interventions
Dehydroepiandrosterone (DHEA), Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

NCT00706719
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
25 mg Androxal, Testim 1%
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 60 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
New York, New York • Purchase, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Not applicable Interventional

Advanced Virtual Exercise Environment Device for Use by Persons With Physical Disabilities

NCT02990507
View directory record Official record
Conditions
Physically Disabled
Interventions
AVEED: Arm rotation, video display, AVEED: Arm rotation, without video display, AVEED: Leg rotation, arm-energy input, video display, AVEED: Leg rotation, arm-energy input, without video display
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Phase 4 Interventional Results available

Effect of Testosterone in Men With Erectile Dysfunction

NCT00512707
View directory record Official record
Conditions
Erectile Dysfunction, Testosterone Deficiency, Diabetes
Interventions
Sildenafil citrate (open label), Testosterone gel, Placebo gel
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Phase 3 Interventional Results available

Time to Eugonadal Range, Time to Steady State and Drying Time

NCT01228071
View directory record Official record
Conditions
Male Hypogonadism
Interventions
testosterone gel 2%
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Tucson, Arizona • Middlebury, Connecticut • Oviedo, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 18, 2026, 11:57 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®

NCT01096329
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Hormones and Decision Making

NCT04865562
View directory record Official record
Conditions
Dyssocial Behavior
Interventions
testosterone propionate, 0.5% cholorbutanol, saline
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions

NCT02110368
View directory record Official record
Conditions
Primary Hypogonadism, Hypogonadotropic Hypogonadism
Interventions
Testosterone Topical Gel, 1.62% Metered Pump, AndroGel (testosterone gel) 1.62% Metered-Dose Pump
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 18, 2026, 11:57 AM EDT
Completed Phase 3 Interventional Results available

Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men

NCT03868059
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
LPCN 1021
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Aventura, Florida • Coral Gables, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 18, 2026, 11:57 AM EDT